ARTICLE | Company News
Salus other research news
October 9, 2000 7:00 AM UTC
Salus received a $100,000 Phase I SBIR grant from the National Heart, Lung and Blood Institute to identify CF targets, for use in developing nucleic acid-based compounds. ...